Xu Z, Feng J, Weng Y, et al. - By analyzing relevant randomized trials, researchers compared immune checkpoint inhibitors (ICI) plus radiotherapy (RT) vs placebo plus RT or ICI alone for the treatment of advanced non-small cell lung cancer and prostate cancer. They analyzed three trials comprising 1,584 patients in this meta-analysis. They found improved overall survival, progression-free survival, and disease control rate in relation to the combination of ICI and RT. Age was a significant predictor of PFS with the combination of ICI and RT, as a significant improvement in PFS was observed in NSCLC patients aged under 65 years. In safety analyses, patients receiving ICI plus RT had a significantly higher incidence of dyspnea and pneumonitis of grade 3 or higher.